# Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)

> **NCT02379052** · PHASE2 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 47 (actual)

## Conditions studied

- Eosinophilic Esophagitis

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02379052
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-12
- **Primary completion:** 2017-02-17
- **Final completion:** 2017-07-10
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2020-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02379052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02379052, "Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02379052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*